Technology
BOXABL Introduces UFO (Unidentified Folding Object), a Concept for Compact, Configurable Off-World Habitats
Published
5 days agoon
By
Concept explores how foldable structures could reduce launch costs while enabling scalable lunar and planetary habitation
LAS VEGAS, June 9, 2026 /PRNewswire/ — Inspired by NASA’s Artimus program and America’s re-commitment to the stars, BOXABL today highlighted UFO (Unidentified Folding Object), a conceptual off-world habitation system designed to address one of the most fundamental challenges of space settlement: transporting livable structures beyond Earth efficiently.
The concept is showcased in BOXABL’s recently released video, “LIVE ON THE MOON (Part 1) — UFO by BOXABL,” which outlines a vision for scalable off-world habitation built around compact transport, modular expansion and adaptable settlement design.
Inspired by the realities of rocket economics, UFO is designed to minimize launch volume and weight while maximizing usable space after deployment. The concept is detailed in the company’s recently disclosed foldable transportable building intellectual property, which describes a habitat capable of folding into a compact launch configuration and expanding into a larger livable structure after deployment.
The foldable habitat packs into a compact launch configuration, expands on-site, and can be linked with other modules to form larger communities for crews, research, tourism, and support infrastructure. The concept further contemplates compatibility with future missions involving organizations such as:
National Aeronautics and Space Administration (NASA)Blue OriginJapan Aerospace Exploration Agency (JAXA)European Space Agency (ESA)Indian Space Research Organisation (ISRO)Korea Aerospace Research Institute (KARI)
The company has indicated that it intends to make the UFO intellectual property available on a royalty-free basis to encourage broader innovation and collaboration in the development of future off-world habitats.
“While the BOXABL mission is wholly focused on Earth, as enthusiasts we saw no viable public disclosed solutions for early-stage habitats off world,” said BOXABL Co-CEO Paolo Tiramani. “Our after-hours skunkworks engineering team got to work to see if we could help early settlers. Issues to solve for are straightforward; rocket cargo-cost is defined by volume and weight so minimize both, and onsite, in this case the moon, solve for ease of setup, flexible configurability, link ability and redundancy from rapid decompression. One of the bigger challenges of deadly long-term cosmic radiation is solved by our Rego-Brix IP that surrounds the structures using easily available local material in a structured easy-to-build manner.”
BOXABL emphasized that the UFO concept was developed by an after-hours skunkworks team operating separately from the company’s day-to-day housing initiatives. While inspired by the potential challenges of future lunar and planetary settlement, the projects do not impact BOXABL’s primary mission of improving housing affordability, accessibility and construction efficiency here on Earth.
This announcement comes ahead of the special meeting for stockholders scheduled later today for both BOXABL and FG Merger II Corp. related to the proposed business combination. If the merger is approved by shareholders and all other customary closing conditions are satisfied, the merger is expected to close and shares of BXBL are expected to begin trading on Nasdaq shortly thereafter.
About BOXABL
BOXABL is transforming the housing market with its modular building systems designed to deliver affordable, high-quality homes at unprecedented speed. Founded in 2017, BOXABL’s innovative approach has attracted worldwide attention as it aims to solve housing challenges for individuals and communities alike. BOXABL’S flagship product, the Casita, is a 361 square foot studio unit with a full kitchen, bathroom, and utilities. The Casita unfolds on-site in less than an hour and is manufactured inside BOXABL’s facilities. BOXABL also has announced the Baby Box, a smaller 120 square foot unit built to RV code, intended for simpler, no foundation setups. BOXABL is also developing stackable and connectable box models that can be combined to form townhomes, multifamily units, or larger single-family homes.
About FG Merger II Corp.
FG Merger II Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
Additional Information About the Proposed Transaction and Where to Find It
Additional information about the transaction, including a copy of the merger agreement has been filed by FGMC in a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”). The proposed transaction has been submitted to shareholders of FGMC for their consideration. FGMC has filed a registration statement on Form S-4 (the “Registration Statement”) with the SEC, which has been declared effective, and a prospectus pursuant to Rule 424(b) under the Securities Act (the “Prospectus”), which includes the definitive proxy statement distributed to FGMC’s shareholders in connection with FGMC’s solicitation of proxies for the vote by FGMC’s shareholders in connection with the proposed transaction and other matters described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to BOXABL’s shareholders in connection with the completion of the proposed transaction. The definitive proxy statement/prospectus and other relevant documents have been mailed to BOXABL stockholders and FGMC shareholders as of the record date established for voting on the proposed transaction. Before making any voting or investment decision, FGMC and BOXABL shareholders and other interested persons are advised to read the definitive proxy statement/prospectus, as well as other documents filed with the SEC by FGMC in connection with the proposed transaction, as these documents contain important information about FGMC, BOXABL and the proposed transaction. Shareholders may obtain a copy of the definitive proxy statement/prospectus, as well as other documents filed by FGMC with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a written request to FG Merger II Corp., 104 S. Walnut Street, Unit 1A, Itasca, Illinois 60143 or to BOXABL 5345 E North Belt Rd Las Vegas NV 89115.
Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “plan,” “project,” “will,” “estimate,” “intend,” “expect,” “believe,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. We have based these forward-looking statements on current expectations and projections about future events. These statements include: projections of market opportunity and market share; estimates of customer adoption rates and usage patterns; projections of development and commercialization costs and timelines; expectations regarding BOXABL’s ability to execute its business model and the expected financial benefits of such model; expectations regarding BOXABL’s ability to attract, retain, and expand its customer base; BOXABL’s deployment of Casita; BOXABL’s expectations concerning relationships with strategic partners, suppliers, governments, regulatory bodies and other third parties; future ventures or investments in companies, products, services, or technologies; development of favorable regulations and government incentives affecting BOXABL’s markets; the potential benefits of the proposed transaction and expectations related to its terms and timing; and the potential for BOXABL to increase in value.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of BOXABL and FGMC.
These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that BOXABL is pursuing an emerging technology, faces significant technical challenges and may not achieve commercialization or market acceptance; BOXABL’s historical net losses and limited operating history; BOXABL’s expectations regarding future financial performance, capital requirements and unit economics; BOXABL’s use and reporting of business and operational metrics; BOXABL’s competitive landscape; BOXABL’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the capital requirements of BOXABL’s business plans and the potential need for additional future financing; BOXABL’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; BOXABL’s reliance on strategic partners and other third parties; BOXABL’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the possibility that required regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of FGMC could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement; the outcome of any legal proceedings or government investigations that may be commenced against BOXABL or FGMC; failure to realize the anticipated benefits of the proposed transaction; the ability of FGMC or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in FGMC’s filings with the SEC. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by BOXABL, FGMC or the combined company resulting from the proposed transaction with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of BOXABL’s and FGMC’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While BOXABL and FGMC may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. Accordingly, undue reliance should not be placed upon these statements.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
An investment in FGMC is not an investment in any of its founders’ or sponsors’ past investments, companies or affiliated funds. The historical results of those investments are not indicative of future performance of FGMC, which may differ materially from the performance of our founders’ or sponsors’ past investments.
Participants in the Solicitation
FGMC, BOXABL and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from FGMC’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of FGMC’s and BOXABL’s shareholders in connection with the proposed transaction as set forth in the joint proxy statement/prospectus filed by FGMC and BOXABL with the SEC. You can find more information about FGMC’s directors and executive officers in FGMC’s and BOXABL’s joint proxy statement/prospectus dated May 12, 2026, and in periodic reports filed by FGMC with the SEC. You can find more information about BOXABL’s directors and executive officers in its Annual Report on Form 10-K, filed with the SEC on March 27, 2026. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources described above.
No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
View original content to download multimedia:https://www.prnewswire.com/news-releases/boxabl-introduces-ufo-unidentified-folding-object-a-concept-for-compact-configurable-off-world-habitats-302795278.html
SOURCE Boxabl
You may like
Technology
Kakunin Announces Cryptographic Compliance Shield for Google Gemini and OpenAI Agent Ecosystems
Published
2 hours agoon
June 14, 2026By
SaaS Compliance Leader Launches First-Class SDK Integrations for Google Antigravity, OpenAI Swarm, and OpenAI Assistants API to Meet Strict MiCA and EU AI Act Standards.
LONDON, June 13, 2026 /PRNewswire-PRWeb/ — Kakunin, the leading compliance infrastructure platform for autonomous AI agents, today announced the release of first-class SDK integrations for Google Antigravity SDK, OpenAI Swarm, and the OpenAI Assistants API.
As organizations move autonomous AI agents from sandboxes to production, securing the tools they run has become a critical operational hurdle. The new integrations allow developers to cryptographically secure and audit agent actions in real time, meeting the strict requirements of upcoming regulations like the EU AI Act and MiCA.
Preventing Agent Drift at the Tool Layer
Instead of relying on prompt engineering or system instructions—which are susceptible to jailbreaks—Kakunin secures agent tool execution at the cryptographic layer:
Pre-Flight Scope Verification: Validates that an agent possesses the required permission scope (e.g., trade.execute, file.write) before executing local code.Active-Agent Enforcement: Dynamically halts execution if the agent’s underlying X.509 certificate has been revoked or suspended.Tamper-Evident Auditing: Automatically logs session starts, prompts, responses, tool successes, and error anomalies.
Ecosystem Compatibility out of the Box
The new releases bring seamless, code-first integrations to the industry’s leading agent frameworks:
Google Antigravity SDK: Hook-based runtime protection that automatically secures Gemini-powered tool workflows.OpenAI Swarm: A lightweight class wrapper (KakuninSwarm) that dynamically gates multi-agent handoffs and task executions.OpenAI Assistants API: A polling-loop helper (handle_assistants_requires_action) that streamlines safety checks and tool output formatting in a single call.
Beyond these core OpenAI and Google environments, the new releases also extend Kakunin’s cryptographic shield to the broader agent development community. Out-of-the-box templates and shims are now available for LangChain (KakuninToolGuard), LlamaIndex (KakuninFunctionToolGuard), CrewAI (KakuninCrewAgent), and AutoGen (KakuninConversableAgent), alongside native middlewares for Next.js API routes and raw client libraries for Go, TypeScript, and Python.
“Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin. “By bringing cryptographic X.509 validation directly to Google’s and OpenAI’s agent loops, we are giving developers the peace of mind to deploy agents in highly regulated environments like fintech and healthcare.”
Availability
The new SDK integrations are available immediately:
Python Package: Available on PyPI via pip install kakunin.Playground Notebooks: Developers can test the integrations in 1-click via the official OpenAI Cookbook and Google Gemini Cookbook.Reference Samples: Available on the public Kakunin Samples Repository.
To learn more about securing your autonomous agent workflows, visit kakunin.ai/docs. or visit Conversational GTM for more enquiries.
Media Contact
Palash Bagchi, Immortal Reality PA LLC, 1 4125437290, ai@kakunin.ai, https://www.kakunin.ai/
View original content to download multimedia:https://www.prweb.com/releases/kakunin-announces-cryptographic-compliance-shield-for-google-gemini-and-openai-agent-ecosystems-302798798.html
SOURCE Kakunin
Technology
District Taco Kicks Off The Summer’s Biggest Soccer Event with Free Delivery Offer
Published
9 hours agoon
June 13, 2026By
App Users can enjoy District Taco at home with free delivery during the world’s biggest soccer tournament.
WASHINGTON, June 13, 2026 /PRNewswire-PRWeb/ — District Taco is bringing the excitement of the world’s biggest soccer tournament straight to fans’ homes with a special promotion designed to make game-day meals even more convenient.
From June 11 through July 19, guests who order delivery through the District Taco app can use promo code ‘SOCCER26’ to receive $5 off their order, effectively offsetting the standard delivery fee and creating a free delivery experience.
Whether cheering on a favorite team, hosting a watch party, or enjoying the match from the couch, fans can enjoy District Taco’s fresh, made-to-order menu without leaving home or the extra delivery cost. “We know fans will be gathering throughout the tournament to watch some of the most exciting matches in the world,” said Osiris Hoil, CEO of District Taco. “This promotion makes it easier and more affordable to enjoy District Taco delivered right to your door so you don’t miss a moment of the action!”
The promotion is part of District Taco’s broader effort to drive digital engagement and app use. Here are the campaign details:
Enter Promo Code: ‘SOCCER26’ when placing the order in-appOffer: $5 off delivery ordersAvailable: June 11 through July 19Valid on: District Taco app delivery orders only (not third-party platforms)
Guests can download the District Taco app here for Apple users and here for Android users!
About District Taco
In 2009, two neighbors got together over some homemade chips, salsa and guacamole and decided to launch District Taco as a food cart. Since then, District Taco has opened multiple locations in Virginia, Maryland, New Jersey, New York, Pennsylvania, Florida, and Washington, DC. Their mission is to serve quality – Yucatán style – Mexican food that is fresh, simple, and healthful, with a fully customizable menu that includes vegetarian, vegan and gluten-free options. At District Taco, food is made fresh daily from the highest quality ingredients. They strive to limit their impact on the environment by serving in environmentally friendly packaging where possible. For more information about District Taco or their menu, and to download the app, visit districttaco.com or follow @districttaco across socials.
Media Contact
Raquel Robinson, District Taco, 1 5712657573, raquel.robinson@districttaco.com, districttaco.com
View original content to download multimedia:https://www.prweb.com/releases/district-taco-kicks-off-the-summers-biggest-soccer-event-with-free-delivery-offer-302799507.html
SOURCE District Taco
Technology
MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations
Published
14 hours agoon
June 13, 2026By
GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life sciences, is showcasing its latest advancements in sequencing, automation and clinical genomics at the European Society of Human Genetics (ESHG) 2026 Conference in Gothenburg, Sweden.
At Booth 352, MGI welcomes researchers, clinicians, laboratory leaders and industry partners to explore its comprehensive portfolio of sequencing and automation solutions while unveiling new initiatives designed to strengthen collaboration across the genomics ecosystem.
Advancing Clinical Genomics Through Partnership
A key highlight of ESHG 2026 is the launch of the MGI NGS Partner Enablement Program, a new initiative designed to connect diagnostic developers, assay providers and laboratory partners seeking to build validated clinical workflows on MGI sequencing platforms.
The program aims to accelerate the development and adoption of regulated next-generation sequencing (NGS) applications by fostering collaborations that simplify workflow implementation, reduce time-to-market and support broader access to precision medicine solutions.
“Clinical genomics is increasingly dependent on strong partnerships across the value chain,” said Fang Chen, General Manager Europe & Africa at MGI. “With the launch of our NGS Partner Enablement Program, we are creating a collaborative framework that brings together assay developers, software providers, automation partners and clinical laboratories to accelerate access to high-quality genomic testing.”
Expanding Automation Capabilities Through OEM Collaborations
At ESHG 2026, MGI is also announcing new Original Equipment Manufacturer (OEM) partnership opportunities on MGI’s DE Bundles (integrated library preparation and sequencing platform), bringing turnkey automation to global partners. The DE Bundle includes the current D4+E25 combination, as well as the new D16 paired with the E25 featuring a new 50M flow cell.
The D16, which will be launched later this year, is a benchtop, mid-to-low throughput library prep system and the upgraded successor to the D4. Retaining the fully enclosed contamination control system, it integrates a single-channel robotic pipetting module to maximize automation. With two sample preparation cartridges each processing 8 samples, the D16 delivers significantly higher throughput. The D16 and E25 systems provide flexible and scalable automation solutions for library construction, sequencing, bioinformatics analysis, streamlining the entire laboratory workflow.
Through this open OEM framework, MGI is enabling customers and solution providers to integrate proven automation technologies into customized workflows tailored to specific clinical and research applications. The OEM program reflects MGI’s commitment to building an open ecosystem that empowers laboratories to increase efficiency, improve standardization and accelerate scientific discovery.
“We are excited to expand the opportunities available to our OEM partners by providing access to the D16 platform, enabling the development of truly walkaway solutions that simplify and automate complex laboratory workflows,” said Wim Vervaeke, OEM Director at Europe & Africa at MGI. “Our innovations, including the PrepALL, E25, and G99, have already sparked new partnerships across the life sciences ecosystem. By combining MGI’s automation expertise with the specialized capabilities of our partners, we are creating integrated solutions that deliver maximum value, efficiency, and convenience for end users.”
Corporate Satellite Symposium Highlights Clinical Genomics, Precision Oncology and Spatial Multi-Omics
As part of ESHG 2026, MGI hosted its Corporate Satellite Symposium, Advancing Diagnostics: From Clinical Implementation to Biomarker Discovery, bringing together leading experts from across Europe to showcase how advanced genomic technologies are being translated into real-world clinical and research impact. The symposium highlighted applications spanning clinical oncology diagnostics, pharmacogenomics, and spatial multi-omics.
Dr. Raquel T. Lima from IPATIMUP (Portugal) presented the clinical value of RNA sequencing for detecting actionable gene fusions in solid tumours, improving diagnostic yield and supporting precision oncology decision-making. Prof. Dr. Andreas Braun from University Hospital Schleswig-Holstein (Germany) shared how spatial biology technologies map the tumour microenvironment in melanoma, revealing tumour heterogeneity, cellular interactions, and mechanisms associated with disease progression and treatment response. Dr. Andrea Conti from BMR Genomics (Italy) explored the opportunities of whole genome sequencing for pharmacogenetic marker evaluation, highlighting how comprehensive genomic approaches can support the implementation of personalised medicine through improved identification of clinically relevant variants.
Together, the presentations demonstrated how genomic and multi-omics technologies are advancing clinical diagnostics, translational oncology research, and precision medicine, while highlighting the growing role of sequencing in delivering actionable insights across healthcare and biomedical research.
Comprehensive Solutions for Genomics and Multi-Omics Research
Visitors to the MGI booth can explore the company’s comprehensive portfolio of sequencing and automation technologies supporting applications across human genetics, oncology, reproductive health, population genomics and multi-omics research.
Highlighting strong market adoption, MGI is showcasing the T7+, its ultra-high-throughput sequencing platform at the conference. Following its official launch for the Europe and Africa region at Analytica 2026 in Munich, the T7+ has gained significant momentum, with 27 units installed worldwide as of the end of 2025. From benchtop to ultra-high-throughput sequencing platforms, as well as advanced laboratory automation solutions, MGI continues to support laboratories seeking high-performance, scalable and cost-effective genomics workflows.
“Our mission extends beyond delivering innovative technologies,” said Dr. Christian Zimmerman, VP Sales Europe & Africa at MGI. “We are focused on building a complete ecosystem that enables our customers to transition seamlessly from research to clinical implementation. The partnerships and initiatives we are launching at ESHG 2026 demonstrate our commitment to making genomic technologies more accessible, integrated and impactful.”
Driving the Future of Precision Medicine in Europe
Europe remains a strategic region for MGI, with growing adoption of genomic technologies across research institutions, healthcare systems and national population initiatives.
Through continued investment in sequencing innovation, automation, clinical partnerships and collaborative ecosystem development, MGI is helping accelerate the transition toward more precise, data-driven healthcare.
As genomics increasingly becomes integrated into routine clinical practice, MGI remains committed to providing the technologies and partnerships necessary to support the next generation of precision medicine.
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.
To learn more, please visit MGI Tech, LinkedIn, X, Instagram, and YouTube.
View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-showcases-expanding-genomics-ecosystem-at-eshg-2026-with-new-ivd-partnering-program-and-oem-collaborations-302799622.html
Kakunin Announces Cryptographic Compliance Shield for Google Gemini and OpenAI Agent Ecosystems
Amazon warning triggered US crackdown on Anthropic AI models: Reports
District Taco Kicks Off The Summer’s Biggest Soccer Event with Free Delivery Offer
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market5 days agoBitcoin bottom? These four charts hint at BTC price dropping to $50K
-
Technology5 days agoALL.SPACE Awards $8.2M Production Order to Sivers Semiconductors for Ka-Band Beamforming ICs
-
Coin Market5 days agoPrivacy push as StarkWare and Sui move toward compliance-ready confidential transfers
-
Technology5 days agoHCLTech launches Cybersecurity Fusion Center in Mississauga to strengthen Canada’s digital resilience
-
Coin Market5 days ago
Bitcoin rebound highlights discount but $162M bid liquidity points to downside risk
-
Coin Market4 days agoSolana Institute CEO says CLARITY Act must shield open-source developers
-
Coin Market4 days agoHyperliquid, Paradigm urge revision of GENIUS money laundering rule
-
Coin Market5 days agoOver 200 crypto firms push Senate to pass CLARITY Act
